Background Carbohydrate antigen 19-9 (CA19-9) is used as a marker to predict recurrence and survival of patients with Pancreatic cancer(PDAC). Recently, fecal elastase-1(FE-1), a marker of pancreatic exocrine function, has been shown to correlate with prognosis in patients with PDAC. However, there have been no studies that have predicted prognosis by combining these two factors. In this study, investigators developed a predictive strategy for prognosis of PDAC using data on preoperative CA19-9 and FE-1 levels.6 Methods The clinical data of patients with resectable pancreatic cancer from two hospitals were analyzed. The cut-off points of preoperative CA19-9 and FE-1 levels were extracted from the Youden index and previous studies (385 U/ml and 100 µg/g stool, respectively). Cox proportional hazard models were used to investigate the association between preoperative tumor marker levels and survival (3-overall survival and 1-year recurrence free survival) after surgery.
Study Type
OBSERVATIONAL
Enrollment
150
Gangnam Severance Hospital
Seoul, South Korea
3yr overall survival
3-year survival rate for patients who underwent surgery for pancreatic cancer
Time frame: Survival period from surgery date, 3 years
1yr disease free survival
Recurrence rate in patients who have undergone surgery for pancreatic cancer within a year
Time frame: Period without recurrence from the date of surgery, one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.